ARTICLE | Clinical News
Neurocrine down on Phase IIb Tourette syndrome miss
December 12, 2018 7:31 PM UTC
Neurocrine Biosciences Inc. (NASDAQ:NBIX) lost $11.93 (14%) to $73.83 on Wednesday after it said valbenazine missed the primary endpoint in the Phase IIb T-Force GOLD trial to treat Tourette syndrome. The move translates to a loss in market cap of almost $1.1 billion.
In 127 pediatric patients with moderate to severe Tourette syndrome, once-daily oral valbenazine failed to significantly improve motor and phonic tic symptoms as measured by Yale Global Tic Severity Scale (YGTSS) Total Tic Score from baseline to week 12 vs. placebo...
BCIQ Company Profiles
BCIQ Target Profiles